WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Sobi - Swedish Orphan Biovitrum AB (publ)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
FiercePharma | March 06, 2020
Biopharma companies are hunkering down as the COVID-19 epidemic breaks out worldwide. In a FiercePharma survey of biopharma companies late last month, most drugmakers said they were simply limiting travel to hard-hit countries such as China, South Korea and Italy. Now, as more cases pop up across the U.S., Europe and Asia, their tone has shifted. GlaxoSmithKline has “instructed all employees to postpone non-critical international business travel until further notice,” a spokesman sai...
Pharma Tech
Bexson Biomedical | October 20, 2022
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, announced Bexson and Stevanato Group a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's 2022 Drug Delivery Innovation Partnership Award. At PDA's annual conference ...
Business Insights
Acorda Therapeutics, Inc. | May 12, 2022
Acorda Therapeutics, Inc. and Biopas Laboratorie announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of ...
Acacia Pharma Group plc | October 12, 2020
Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE